Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene to Appeal Third Wave Patent Infringement Ruling, Sues Third Wave for Infringement

NEW YORK, Sept. 5 (GenomeWeb News) - Stratagene said last week that it will appeal a recent court decision that found the company had infringed patents held by Third Wave Technologies.

 

As reported by GenomeWeb News, last week a jury has determined that Stratagene's quantitative PCR and RT-PCR reagents using its FullVelocity technology infringe two patents held by Third Wave Technologies as part of its Invader technology.

 

Stratagene said that it was informed that the jury had awarded Third Wave $5.29 million in damages. The company said that the jury's verdict and the damages awarded were not supported by the facts of the case and, as a result, it will appeal the decision.

 

Stratagene also said that it has served Third Wave with a patent infringement suit filed in May. That suit alleges Third Wave has infringed certain Stratagene technology related to the quantitative detection of nucleic acids, and seeks monetary damages and a permanent injunction against continued infringement.

 

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.